Institutional members access full text with Ovid®

Share this article on:

COGNITIVE IMPAIRMENT AMONG OLDER ADULTS WITH LATE-LIFE SCHIZOPHRENIA OR BIPOLAR DISORDER

Palmer, Barton W.; Loughran, Casey I.; Meeks, Thomas W.

CONTINUUM: Lifelong Learning in Neurology: April 2010 - Volume 16 - Issue 2, Dementia - p 135-152
doi: 10.1212/01.CON.0000368216.09706.6b
Article

Neurologists are increasingly faced with the daunting task of disentangling dementia from primary psychiatric conditions or recognizing their coexistence in older patients. Both schizophrenia and bipolar disorder are characterized by substantial intergroup cognitive heterogeneity among older and younger patients. In schizophrenia, deficits in many cognitive domains are common; however, "rapid forgetting," loss of crystallized knowledge, and greater than age-normal declines in cognitive function are rare and warrant careful evaluation for secondary causes. The cognitive deficits associated with bipolar disorder tend be most severe during acute affective episodes, but some deficits tend to persist even during periods of relative euthymia. Lifetime number of affective episodes in bipolar disorder may adversely affect cognitive functions in bipolar disorder, but severe deficits and/or substantive declines over a period of a few years are unusual and warrant careful evaluation for secondary causes.

Relationship Disclosure: Dr Palmer and Ms Loughran have nothing to disclose. Dr Meeks has received personal compensation for serving as the assistant to the editor of American Journal of Geriatric Psychiatry.

Unlabeled Use of Products/Investigational Use Disclosure: Dr Palmer, Ms Loughran, and Dr Meeks discuss the unlabeled use of medication for cognitive impairment and the use of psychotropics in the treatment of psychotic symptoms secondary to dementia or a general medical condition. Dr Palmer, Ms Loughran, and Dr Meeks discuss the unlabeled use of cholinesterase inhibitors for treatment of Lewy body dementia, quetiapine for treatment of psychosis secondary to Lewy body dementia, and olanzapine for treatment of psychosis secondary to a medical condition.

© 2010 American Academy of Neurology
You currently do not have access to this article

To access this article:

Note: If your society membership provides full-access, you may need to login on your society website